Slides
Page 1
S E Q U E N T S C I E N T I F I C L I M I T E D 11th Feb 2025 INVESTOR PRESENTATION Q3 FY25
Page 2
The performance of SeQuent in Q3 FY25 continues to build on the company’s strong return to growth and profitability across all parts of the business. We remain positive on the sustenance of the current momentum. This is further strengthened by the continuing growth of the Viyash business, as we prepare to build a differentiated global pharmaceuticals platform with end to end capabilities . Our Q3FY25 revenues saw a growth of 18.7% Year-on-Year (“YoY”) to Rs 3,908 mn with strong double digit growth in both Formulations and API. When aggregated for the first nine months the overall revenue growth of the company is at 14.0 % YoY. Our gross margins have continued to trend upwards as we register the benefits of pricing, product mix and market expansion. The ongoing initiatives of cost improvement have further helped in the improvement in profitability. Our EBITDA (pre-esop) of INR 494 Mn represents a 63.8% growth YoY for the quarter, while the first nine months EBITDA (pre-esop) at Rs 1424 Mn showed a growth of 116.5% YoY. The global formulations business grew at 19.8% YoY for the quarter, driven by volume growth in Europe, better product mix in Turkey, and field expansion in India. The API business witnessed strong interest in the deworming segment, and registered a YOY revenue growth 17.7 % for the quarter. Our facilities in Turkey and Mahad received approvals of global agencies, thereby strengthening their readiness to service new customers. In September 2024, we announced the proposal for a strategic merger with Viyash Life Sciences Private Limited (“Viyash”). We have begun to receive some key approvals from regulatory agencies and expect to complete the process before December 2025, subject to statutory approvals. Viyash Life Sciences continues to deliver strong performance , with a revenue growth of 19% YoY for Q3 FY25 and EBITDA ( pre Esop ) growth of 68% YoY for this quarter, while accelerating the rate of new filings and new product launches. We are very excited about the potential of the merged entity, which will create a strong R&D engine for growth, improve margins and enhance our Go to Market capabilities. Rajaram Narayanan Managing Director and CEO Sequent Q3 FY25 – Continued growth in revenue and profitability